varoglutamstat (PQ912)

P2, N=112, Terminated, Vivoryon Therapeutics N.V. | N=414 --> 112 | Active, not recruiting --> Terminated; It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.

P2, N=414, Active, not recruiting, Vivoryon Therapeutics N.V. | Recruiting --> Active, not recruiting

P2, N=414, Recruiting, Vivoryon Therapeutics N.V. | Phase classification: P2b --> P2 | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024

P2, N=259, Completed, Vivoryon Therapeutics N.V. | Active, not recruiting --> Completed | Phase classification: P2b --> P2

Its photothermal therapy can promote the infiltration of T lymphocytes in addition to ablating tumor cells and AUNP-12 and PQ912 further boost both the innate and adaptive immune reactions by cutting off PD-L1 and CD47 signals, respectively. In contrast to earlier single immunotherapy, the nanocomposites exhibit a stronger anti-tumor immune effect without obvious autoimmune side effects, promoting infiltration of T lymphocyte into the tumor site and strengthening phagocytosis of macrophages, even more exciting, significantly reversing pro-tumor M2-like tumor-associated macrophages (TAMs) to anti-tumor M1-like TAMs. The research may provide a promising strategy to develop high-efficient and low-toxic immunotherapy based on nanotechnology.